Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $9.29 USD
Change Today -0.02 / -0.21%
Volume 764.0
EVTCY On Other Exchanges
As of 8:10 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

evotec ag - spon adr (EVTCY) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/6/15 - $9.31
52 Week Low
10/16/14 - $6.26
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EVOTEC AG - SPON ADR (EVTCY)

Related News

No related news articles were found.

evotec ag - spon adr (EVTCY) Related Businessweek News

No Related Businessweek News Found

evotec ag - spon adr (EVTCY) Details

Evotec (US), Inc. discovers, develops, and commercializes drugs for the treatment of neurological and inflammatory diseases in the United States. It operates in preclinical research and development, including molecular biology, medicinal chemistry, in vitro and in vivo pharmacology, drug metabolism, pharmacokinetics, toxicology, and informatics. The company’s proprietary preclinical programs are focused on identifying antagonists of selected purinergic receptors as novel potential treatments for a range of pain and inflammatory conditions. It focuses on identifying and developing treatments for pains, such as osteoarthritic pain or pain associated with osteoarthritis, and neuropathic pain or nerve pain. The company offers VR1 antagonist program that develops and maintains various pain states, including inflammatory and neuropathic pain; P2X3 and P2X2/3 receptors that are therapeutic targets for medical needs in the areas of chronic pain and bladder dysfunction; and P2X7, which represents molecular target for new therapies in the areas of rheumatoid arthritis and inflammatory bowel disease. It has strategic alliances with Pfizer, Inc. for the research, development, and commercialization of small molecule compounds that target VR1 for the potential treatment of pain, and other diseases and disorders. Evotec (US), Inc. was formerly known as Renovis, Inc. As a result of the acquisition of Renovis, Inc. by Evotec AG, Renovis, Inc.'s name was changed. The company was founded in 2000 and is based in South San Francisco, California. As of May 2, 2008, Evotec (US), Inc. operates as a subsidiary of Evotec AG.

67 Employees
Last Reported Date: 03/17/08
Founded in 2000

evotec ag - spon adr (EVTCY) Top Compensated Officers

Executive Chairman and Principal Executive Of...
Total Annual Compensation: --
Co-Founder, Director and Chairman of Nominati...
Total Annual Compensation: --
Senior Vice President of Research and Develop...
Total Annual Compensation: --
Vice President of Legal Affairs and Associate...
Total Annual Compensation: --
Senior Vice President of Human Resources and ...
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

evotec ag - spon adr (EVTCY) Key Developments

Evotec US Inc Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Evotec US Inc Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Evotec (US) Inc. and Medicines for Malaria Venture Announce a Long-Term Compound Management Collaboration

Evotec AG announced the start of a multi-year compound management agreement between Evotec (US) Inc. and Medicines for Malaria Venture ("MMV") in support of MMV's Malaria and Pathogen Box initiatives. These two innovative initiatives are expected to revolutionise the field of drug discovery for malaria and neglected diseases. In this collaboration, Evotec will leverage its long-standing compound management services to support MMV's efforts to establish, maintain and distribute vital research tools to the global malaria research community. Evotec delivers an industrialised and comprehensive compound management infrastructure to support all aspects of this collaboration.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVTCY:US $9.29 USD -0.02

EVTCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EVTCY.
View Industry Companies

Industry Analysis


Industry Average

Valuation EVTCY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.4x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 54.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOTEC AG - SPON ADR, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at